Remedy Cell

Fibrosis lungs
#Artificial intelligence (AI) #Deep learning #Idiopathic pulmonary fibrosis #Partnership #Phase I trial #Qureight #Remedy Cell

Deep learning provides enhanced imaging analysis in IPF trial

Qureight and biopharmaceutical company Remedy Cell have agreed a partnership to validate RC-0315’s mechanism of action in idiopathic pulmonary fibrosis (IPF).  The primary objective of the RC-0315 Phase Ib clinical study is to measure drug safety and tolerability.   The study’s exploratory objectives will assess the… Read More

#News